Order Article Reprints

López-Arencibia A, Bethencourt-Estrella CJ, Berenguer D, Domínguez-de-Barros A, Alcover MM, Sessa M, Halbaut L, Fisa R, Calpena-Campmany AC, Córdoba-Lanús AE, et al. In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment. Pathogens. 2024; 13(8):712. https://doi.org/10.3390/pathogens13080712

López-Arencibia, Atteneri, Carlos J. Bethencourt-Estrella, Diana Berenguer, Angélica Domínguez-de-Barros, M. Magdalena Alcover, Marcella Sessa, Lyda Halbaut, Roser Fisa, Ana Cristina Calpena-Campmany, A. Elizabeth Córdoba-Lanús, and et al. 2024. "In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment" Pathogens 13, no. 8: 712. https://doi.org/10.3390/pathogens13080712

López-Arencibia, A., Bethencourt-Estrella, C. J., Berenguer, D., Domínguez-de-Barros, A., Alcover, M. M., Sessa, M., Halbaut, L., Fisa, R., Calpena-Campmany, A. C., Córdoba-Lanús, A. E., Lorenzo-Morales, J., Riera, C., & Piñero, J. E. (2024). In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment. Pathogens, 13(8), 712. https://doi.org/10.3390/pathogens13080712